Pharmaceutical - Newron Pharma


Current filters:

Newron Pharma

Popular Filters

Safinamide marketing application submitted to Swissmedic


Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

Patent expiries will push Parkinson’s drug market lower by 2019


Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Newron and Zambon file for EU approval of Parkinson’s drug safinamide


Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

EuropeNeurologicalNewron PharmaNorth AmericaPharmaceuticalRegulationsafinamideZambon

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Newron executes safinamide deal with Zambon; new Ph III data; management changes


In what was a busy news day for Italian drug developer Newron Pharmaceuticals SpA (SIX: NWRN), the company…

FinancialLicensingManagementNeurologicalNewron PharmaPharmaceuticalResearchsafinamideZambon

Newron licenses safinamide to Zambon for EU and USA


Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration…

LicensingMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalsafinamideZambon

Newron gets new partner for safinamide


Italy-headquartered R&D firm Newron Pharmaceuticals (SIX: NWRN) yesterday revealed that it has agreed…

Asia-PacificLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalsafinamide



Back to top